EMAIL THIS PAGE TO A FRIEND

The Journal of antimicrobial chemotherapy

Efficacy of the novel oxazolidinone compound FYL-67 for preventing biofilm formation by Staphylococcus aureus.


PMID 24997316

Abstract

Infections of hospitalized patients caused by biofilms formed by Staphylococcus aureus represent a major problem. Using in vitro and in vivo biofilm models, we evaluated the efficacy of the novel oxazolidinone FYL-67, by using linezolid (the only clinically approved oxazolidinone antibiotic) as a control, for inhibiting S. aureus biofilm formation. Antibiofilm activity was determined using strains of methicillin-susceptible S. aureus and methicillin-resistant S. aureus. We studied the mechanism(s) and pharmacodynamics of antibiofilm activity as follows: (i) effects of pre- and post-exposure to FYL-67 or linezolid on biofilm formation; (ii) the effect of FYL-67 on biofilm structure; (iii) the role of FYL-67 in biofilm composition; (iv) effects on cell morphology; and (v) efficacy of FYL-67 and linezolid using an in vivo murine model of catheter infection. FYL-67 effectively inhibited biofilm formation using in vitro and in vivo assays. Our data suggest that oxazolidinone compounds, such as FYL-67, may serve as antibiofilm agents.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

C3250000
Cyclophosphamide, European Pharmacopoeia (EP) Reference Standard
C7H15Cl2N2O2P · H2O